NHS England to Roll Out Chickenpox Vaccine in January 2026 as Part of New MMRV Immunization Program
Key Insights
The NHS will introduce a chickenpox vaccine as part of a new combined MMRV (measles (search), mumps (search), rubella (search) and varicella (search)) vaccine starting January 2026, protecting approximately 500,000 children annually.
The vaccine rollout is expected to save the NHS £15 million per year in treatment costs while preventing an estimated £24 million in lost income and productivity from parents taking time off work.
This marks the first addition of protection against another disease to the routine childhood vaccination programme since 2015, with the MMRV vaccine (search) eventually replacing the current MMR vaccine.
NHS England (search) has announced plans to introduce a chickenpox vaccine into the routine childhood vaccination programme starting January 2026, marking the first expansion of the national immunization schedule since 2015. The vaccine, currently available privately for around £150, will be integrated into a new combined MMRV (measles (search), mumps (search), rubella (search) and varicella (search)) vaccine that will eventually replace the existing MMR vaccine.
Economic and Health Impact
The rollout is projected to deliver significant economic benefits, with the Department of Health and Social Care estimating that chickenpox (search) currently causes £24 million in lost income and productivity annually across the UK as parents take time off work to care for infected children. The NHS expects to save £15 million per year in treatment costs once the vaccination programme is fully implemented.
The new MMRV vaccine (search) will be offered at GP practices and is expected to protect approximately 500,000 children each year. It will be administered at 12 months and 18 months, following the same schedule as the current MMR vaccine.
Clinical Significance
Dr Gayatri Amirthalingam, deputy director of immunisation at the UK Health Security Agency (search) (UKHSA), emphasized the clinical importance of the programme: "Most parents probably consider chickenpox (search) to be a common and mild illness, but for some babies, young children and even adults, chickenpox can be very serious, leading to hospital admission and tragically, while rare, it can be fatal."
While chickenpox (search) typically presents as an itchy, spotty rash accompanied by high temperature, loss of appetite, and general malaise, complications can include bacterial infections such as group A strep (search). In rare cases, the virus can cause brain swelling, serious lung inflammation, and stroke, sometimes resulting in death.
International Context and Implementation
The chickenpox vaccine is already incorporated into routine vaccination schedules in multiple countries, including Germany, Australia, Canada, and the United States. The Joint Committee on Vaccination and Immunisation (search) (JCVI) recommended the introduction of the vaccine to the NHS in November 2023.
Health Minister Stephen Kinnock highlighted the broader benefits of the programme: "We're giving parents the power to protect their children from chickenpox (search) and its serious complications, while keeping them in nursery or the classroom where they belong and preventing parents from scrambling for childcare or having to miss work."
Vaccination Coverage Challenges
The announcement comes amid concerning data showing declining vaccination rates across England. New UKHSA figures reveal that none of the main childhood vaccines reached the 95% uptake target in 2024/25. MMR vaccine coverage among five-year-olds dropped to 91.9% for the first dose and 83.7% for both doses, representing the lowest levels since 2010/11 and 2009/10 respectively.
Amanda Doyle, national director for primary care and community services at NHS England (search), described the chickenpox vaccine introduction as "a hugely positive moment for families as the NHS gets ready to roll out a vaccine to protect children against chickenpox (search) for the first time, adding to the arsenal of other routine jabs that safeguard against serious illness."